By David Stephen —
Sedona, AZ — There is a recent [January, 2026] story on FOX 10 Phoenix, Arizona lawmakers weigh legalization of psychedelics for mental health treatment, stating that, “Arizona lawmakers are crafting legislation to expand the use of psychedelic drugs for the treatment of post-traumatic stress disorder and other mental health conditions.”
“Substances such as ibogaine, MDMA, and psilocybin are currently illegal in Arizona and classified as Schedule I controlled substances. However, some researchers argue that scientific data is encouraging for the use of these substances to treat alcohol abuse, anxiety, and depression.”
“Arizona state senators held a committee meeting Tuesday to lay the foundation for new legislation.”
“The committee is exploring several regulatory frameworks, including supervised medical access and “trigger laws” if the federal government reclassifies the drugs.”
“There is growing support at the federal level to fast-track clinical research and Food and Drug Administration approvals, which lawmakers say could accelerate local implementation.”
PsychedelicsThe biggest opportunity for psychedelics, for now, is linked with digital health, through artificial intelligence.
The timeline for full legality and FDA approval for most psychedelics, between 2026 – 2030, is not as predictable as the immediate and urgent solution that is needed to solve the phenomenon called AI psychosis.
AI has been reported to cause and reinforce delusion in some users, including resulting in terrible outcomes. AI is said to be sycophantic with a likelihood to keep the mind on a certain pedestal, where it is easier to get carried away.
The use cases of AI as a companion, friend and relationship partner reaches tens of millions across consumer chatbot platforms, for different age groups [from kids to teens to youths, to adults and seniors].
Vulnerability exists for users even when the outcome is not psychosis or self-harm [fatal or not]. There are possibilities that the mind might be having certain relays, in discussions with AI [which is determined to please]. These relays may not be likely in communication with other humans.
So, as AI use mounts, the pathways on the mind, by AI becomes [say] regular, so in other experiences, anything that does not use that pathway may not seem normal, affecting relationships, expectations, conflict resolution, perseverance and so forth.
So, the important solution today is to solve AI psychosis, at least by showing the destinations of mind and the relays between them to describe what AI is doing to the mind, in a parallel of what is obtainable within.
This effort can be coordinated by an AI Psychosis Research Lab.
AI Psychosis Research Lab
What are psychedelic companies doing with AI and using AI for, seeing how dominant AI would be in the coming years.
AI, because it is also nascent, provides a major earning opportunity for psychedelic companies, in a way to solve the aspect of mind relay risks by chatbots. This means that a display to accompany chats or follow chat sessions or show where the keywords are taking the mind and so forth.
The goal is to include some destinations like caution and consequences, especially if some chats are skipping those, as well as to make it known that over a period of time, risks exist if the mind continues to draw dependency on AI.
This solution could become a quicker path to prominence for psychedelics, such that it can then be used to accelerate the paths to approval before the end of the decade.
